Hepatitis C Virus Core Protein Inhibits Interleukin 12 and Nitric Oxide Production from Activated Macrophages

INTERFERON 0301 basic medicine 570 Transcription, Genetic 610 Mice, Transgenic Hepacivirus BLOOD MONONUCLEAR-CELLS Nitric Oxide DENDRITIC CELLS Monocytes Cell Line Interferon-gamma Mice 03 medical and health sciences Virology INFECTION KINASE IMMUNE-RESPONSE Animals Humans HEMATOPOIETIC-CELLS IN-VIVO Tumor Necrosis Factor-alpha IL-12 PRODUCTION Macrophages Viral Core Proteins T-HELPER CELLS Macrophage Activation Interleukin-12 Recombinant Proteins 3. Good health Macrophages, Peritoneal Lymphocyte Culture Test, Mixed
DOI: 10.1006/viro.2000.0694 Publication Date: 2002-09-19T13:00:16Z
ABSTRACT
A characteristic feature of hepatitis C virus (HCV) infection is a high frequency of persistence and the progression to chronic liver diseases. Recent data suggest that prevalent T helper (Th) 2 immunity as well as weak HCV-specific T-cell response is associated with viral persistence. Here, we showed that the production of interleukin 12 (IL-12) and nitric oxide (NO) that is critical for the induction of Th1 and innate immunity, but not that of tumor necrosis factor alpha (TNF-alpha), was significantly suppressed in both HCV core-expressing macrophage cell lines and mouse peritoneal macrophages treated with recombinant core protein. In addition, IL-12 p40 promoter activity was repressed by the presence of HCV core in macrophages stimulated with lipopolysaccharride (LPS) following IFN-gamma treatment, indicating that IL-12 production may be downregulated at the transcriptional level. We also found that proliferation of T cells and IFN-gamma production in mixed lymphocyte reactions (MLR) with core-expressing cells were inhibited. Taken together, our results suggest that HCV core protein could play roles in suppressing the induction of Th1 immunity through inhibition of IL-12 and NO production.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (48)
CITATIONS (53)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....